Advertisement
Australia markets close in 3 hours 19 minutes
  • ALL ORDS

    7,772.40
    -126.50 (-1.60%)
     
  • ASX 200

    7,522.70
    -119.40 (-1.56%)
     
  • AUD/USD

    0.6373
    -0.0053 (-0.82%)
     
  • OIL

    86.06
    +3.33 (+4.03%)
     
  • GOLD

    2,414.40
    +16.40 (+0.68%)
     
  • Bitcoin AUD

    95,046.57
    -1,659.14 (-1.72%)
     
  • CMC Crypto 200

    1,243.01
    +357.47 (+37.47%)
     
  • AUD/EUR

    0.5999
    -0.0031 (-0.52%)
     
  • AUD/NZD

    1.0870
    -0.0005 (-0.05%)
     
  • NZX 50

    11,755.46
    -80.58 (-0.68%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,142.52
    -243.35 (-1.49%)
     
  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock

OraSure Technologies (OSUR) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this diagnostic test maker, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

Consensus earnings estimates for the next quarter and full year have moved considerably higher for OraSure, as there has been strong agreement among the covering analysts in raising estimates.

ADVERTISEMENT

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $0.16 per share, which is a change of +157.14% from the year-ago reported number.

Over the last 30 days, two estimates have moved higher for OraSure compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 321.43%.

Current-Year Estimate Revisions

The company is expected to earn $0.07 per share for the full year, which represents a change of +128% from the prior-year number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, two estimates have moved up for OraSure versus one negative revision. This has pushed the consensus estimate 117.07% higher.

Favorable Zacks Rank

The promising estimate revisions have helped OraSure earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

Investors have been betting on OraSure because of its solid estimate revisions, as evident from the stock's 17.4% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research